Skip to main
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is positioned for success in the biotechnology industry with its strong pipeline of precision oncology therapies. The company's collaborations and license revenue, coupled with its positive clinical data, demonstrate its potential for growth. The potential for a strategic partnership or acquisition, and the potential for vopimetostat to become a first-line therapy for KRAS-mutated pancreatic cancer further support our positive outlook for Tango Therapeutics.

Bears say

Tango Therapeutics is a pre-commercial biotech company with a negative outlook due to several key factors. These include the potential for negative clinical results with lead asset TNG462, risks associated with advancing pipeline candidates, and the potential for failure to achieve favorable clinical results with other candidates. Additionally, the company may face significant competition in the oncology market, which could impact its revenue potential. There is also a possibility that the FDA could delay or reject approval of vopimetostat, creating downside risk for the company. Given these factors, the high valuation and price target for Tango Therapeutics may not be achievable.

Tango Therapeutics (TNGX) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 11 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.